Keeps BioPharma

Keeps BioPharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Keeps BioPharma (256940.KQ) as of Oct 29, 2026 is 509.01 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -169.90 % — a change of -399.60% (higher).

FCF Conversion

509.01 %

YoY

-399.60%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Keeps BioPharma is 2025 509.01 % . FCF Conversion Rate (FCF/EBITDA) of Keeps BioPharma was 2024 -169.90 % . It decreases by -399.60% higher compared to the previous year.

The Keeps BioPharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-42.99 KRW
Jan 1, 2019
217.98 KRW
Jan 1, 2020
115.55 KRW
Jan 1, 2021
55.30 KRW
Jan 1, 2022
8.46 KRW
Jan 1, 2023
-28.70 KRW
Jan 1, 2024
-169.90 KRW
Jan 1, 2025
509.01 KRW
The Keeps BioPharma FCF Conversion history
YEARFCF ConversionYoY
509.01 %-399.60%
-169.90 %+492.01%
-28.70 %-439.30%
8.46 %-84.71%
55.30 %-52.14%
115.55 %-46.99%
217.98 %-607.03%
-42.99 %-116.09%
267.26 %+1,398.76%
17.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Keeps BioPharma Stock analysis

What does Keeps BioPharma do? Keeps BioPharma Inc, operating under the KPS Corp brand, is headquartered in Hwaseong, South Korea. Listed on the stock exchange in December 2016, the company engages in the manufacture and sale of specialized machinery for flat panel displays. With a workforce of 49 employees, its product portfolio includes mask stretchers, support mask stretchers, total pitch inspection systems, open mask tension welders, lamination and de-lamination systems, inkjet printers, diffusion systems, and panel inspection systems. The firm operates within the Information Technology sector, specifically in the Semiconductors industry, providing essential equipment for display manufacturing processes. Keeps BioPharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Keeps BioPharma stock

FCF Conversion Rate (FCF/EBITDA) of Keeps BioPharma is 509.01 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Keeps BioPharma changed from -169.90 % to 509.01 %, representing a -399.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Keeps BioPharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Keeps BioPharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Keeps BioPharma

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Keeps BioPharma